Reata Pharmaceuticals

Since its founding in 2002, Reata has been leading the dawn of a new era in pharmaceutical approaches for the treatment of serious and life-threatening diseases. We are dedicated to understanding the biology that underlies disease.

We strive to understand complex, interconnected molecular pathways with significant potential to impact human pathophysiology, and apply our deep understanding of the cellular response to injury to develop innovative medicines.Our scientific mission is to identify, develop, and commercialize small molecule therapeutics with novel mechanisms of action for the treatment of severe life-threatening diseases that have few or no approved therapies.

J. Warren Huff is the Chairman, Chief Executive Officer and President of Reata. He has served as our sole Chief Executive Officer, President and as Chairman of the Board since our founding in 2002. Prior to founding Reata, Mr. Huff served as Chief Executive Officer in a number of biotechnology and information technology start-up enterprises.

Reata's commitment to ethics and compliance guides our employees every day in their work to bring life-changing therapies to patients. This commitment is a responsibility shared equally across the organization and demands the highest standards of conduct from the entire Reata team. If you are aware of a potential violation of law, or of any of Reata's policies, please call the Compliance Hotline, or document your concern using the weblink below.

Reata has active clinical, preclinical, and internal discovery programs in many significant disease areas. We focus on molecular pathways that regulate cellular metabolism, inflammation, and the response to cellular stress in serious and life-threatening diseases that have limited or no approved therapies.

We are developing Nrf2 activators to treat chronic diseases characterized by mitochondrial dysfunction, oxidative stress, and chronic inflammation. Bardoxolone methyl and omaveloxolone are investigational Nrf2 activators that selectively bind to Keap1, a protein that governs the activity of Nrf2 in response to cellular stress.